An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio

References

• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–480. doi: 10.1038/nrc2394
   PubMed Web of Science ®Google Scholar
• Ashman N, Bargh JD, Spring DR. Non-internalising antibody–drug conjugates. Chem Soc Rev. 2022;51(22):9182–9202. doi: 10.1039/D2CS00446A
   PubMed Web of Science ®Google Scholar
• Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209. doi: 10.1186/bcr3621
   PubMed Web of Science ®Google Scholar
• Hoffmann RM, Coumbe BG, Josephs DH, et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology. 2018;7(3):e1395127. doi: 10.1080/2162402X.2017.1395127
   PubMed Web of Science ®Google Scholar
• Shim H. Bispecific antibodies and antibody–drug conjugates for cancer therapy: technological considerations. Biomolecules. 2020;10(3):360. doi: 10.3390/biom10030360
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang F, Lu A, et al. Linkers having a crucial role in antibody–drug conjugates. Int J Mol Sci. 2016;17(4):561. doi: 10.3390/ijms17040561
   PubMed Web of Science ®Google Scholar
• Chen H, Lin Z, Arnst KE, et al. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22(8):1281. doi: 10.3390/molecules22081281
   PubMed Web of Science ®Google Scholar
• Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib Ther. 2018;1(2):43–53. doi: 10.1093/abt/tby007
   Google Scholar
• Dugal-Tessier J, Thirumalairajan S, Jain N. Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates. J Clin Med. 2021;10(4):838. doi: 10.3390/jcm10040838
   PubMed Web of Science ®Google Scholar
• Beckford-Vera D, McCloskey M, Li J, et al. Abstract 5040: novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors. Cancer Res. 2023;83(7_Supplement):5040–5040. doi: 10.1158/1538-7445.AM2023-5040
   Web of Science ®Google Scholar
• Hingorani DV, Crisp JL, Doan MK, et al. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials. 2020;248:120032. doi: 10.1016/j.biomaterials.2020.120032
   PubMed Web of Science ®Google Scholar
• He L, Wang L, Wang Z, et al. Immune modulating antibody–drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 2021;64(21):15716–15726. doi: 10.1021/acs.jmedchem.1c00961
   PubMed Web of Science ®Google Scholar
• McPherson MJ, Hobson AD. Pushing the Envelope: Advancement of ADCs Outside of Oncology. In: Tumey L, editor. Antibody-Drug Conjugates. Methods in Molecular Biology. Vol. 2078. New York, NY: Humana; 2020. doi: 10.1007/978-1-4939-9929-3_2
   Google Scholar
• Wagh A, Song H, Zeng M, et al. Challenges and new frontiers in analytical characterization of antibody-drug conjugates. MAbs. 2018;10(2):222–243. doi: 10.1080/19420862.2017.1412025
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–7070. doi: 10.1158/1078-0432.CCR-04-0789
   PubMed Web of Science ®Google Scholar
• Deslignière E, Diemer H, Erb S, et al. A combination of native LC-MS approaches for the comprehensive characterization of the antibody-drug conjugate trastuzumab deruxtecan. Front Biosci Landmark. 2022;27(10):290. doi: 10.31083/j.fbl2710290
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, et al. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;3(2):161–172. doi: 10.4161/mabs.3.2.14960
   PubMed Web of Science ®Google Scholar
• Stephan JP, Kozak KR, Wong WLT. Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates. Bioanalysis. 2011;3(6):677–700. doi: 10.4155/bio.11.30
   PubMed Web of Science ®Google Scholar
• Sun X, Ponte JF, Yoder NC, et al. Effects of drug–antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody–maytansinoid conjugates. Bioconjugate Chem. 2017;28(5):1371–1381. doi: 10.1021/acs.bioconjchem.7b00062
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnol. 2008;26(8):925–932. doi: 10.1038/nbt.1480
   PubMed Web of Science ®Google Scholar
• Strop P, Liu S-H, Dorywalska M, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161–167. doi: 10.1016/j.chembiol.2013.01.010
   PubMed Web of Science ®Google Scholar
• Axup JY, Bajjuri KM, Ritland M, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Nat Acad Sci. 2012;109(40):16101–16106. doi: 10.1073/pnas.1211023109
   PubMed Web of Science ®Google Scholar
• Ko MJ, Song D, Kim J, et al. N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability. MAbs. 2021;13(1):1914885. doi: 10.1080/19420862.2021.1914885
   PubMed Web of Science ®Google Scholar
• Mindt TL, Jungi V, Wyss S, et al. Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjugate Chem. 2008;19(1):271–278. doi: 10.1021/bc700306n
   PubMed Web of Science ®Google Scholar
• Dennler P, Schibli R, Fischer E. Enzymatic Antibody Modification by Bacterial Transglutaminase. In: Ducry L, editor. Antibody-Drug Conjugates. Methods in Molecular Biology. Vol. 1045. Totowa, NJ: Humana Press; 2013. doi: 10.1007/978-1-62703-541-5_12
   Google Scholar
• Dimasi N, Fleming R, Zhong H, et al. Efficient preparation of site-specific antibody–drug conjugates using cysteine insertion. Mol Pharmaceut. 2017;14(5):1501–1516. doi: 10.1021/acs.molpharmaceut.6b00995
   PubMed Web of Science ®Google Scholar
• Sussman D, Westendorf L, Meyer D, et al. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Protein Eng Des Sel. 2018;31(2):47–54. doi: 10.1093/protein/gzx067
   PubMed Web of Science ®Google Scholar
• Robert P, Lyon RP, Meyer DL, et al. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. In: Dane Wittrup K, Verdine GL, editors. Methods in enzymology. Vol. 502. Academic Press; 2012. p. 123–138. doi: 10.1016/B978-0-12-416039-2.00006-9
   Google Scholar
• Tumey LN, Li F, Rago B, et al. Site selection: a case study in the identification of optimal cysteine engineered antibody drug conjugates. AAPS J. 2017;19(4):1123–1135. doi: 10.1208/s12248-017-0083-7
   PubMed Web of Science ®Google Scholar
• Nanna AR, Li X, Walseng E, et al. Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. Nat Commun. 2017;8(1):1112. doi: 10.1038/s41467-017-01257-1
   PubMedGoogle Scholar
• VanBrunt MP, Shanebeck K, Caldwell Z, et al. Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody–drug conjugates using click cycloaddition chemistry. Bioconjugate Chem. 2015;26(11):2249–2260. doi: 10.1021/acs.bioconjchem.5b00359
   PubMed Web of Science ®Google Scholar
• Van Geel R, Wijdeven MA, Heesbeen R, et al. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody–drug conjugates. Bioconjugate Chem. 2015;26(11):2233–2242. doi: 10.1021/acs.bioconjchem.5b00224
   PubMed Web of Science ®Google Scholar
• Li X, Nelson CG, Nair RR, et al. Stable and potent selenomab-drug conjugates. Cell Chem Biol. 2017;24(4):433–442. e6. doi: 10.1016/j.chembiol.2017.02.012
   PubMed Web of Science ®Google Scholar
• Groff D, Carlos NA, Chen R, et al. Development of an E. coli strain for cell‐free ADC manufacturing. Biotechnol Bioeng. 2022;119(1):162–175. doi: 10.1002/bit.27961
   PubMed Web of Science ®Google Scholar
• Shah NN, Krishnan AY, Shah ND, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Blood. 2019;134(Supplement_1):5329. doi: 10.1182/blood-2019-122754
   Google Scholar
• Okeley NM, Toki BE, Zhang X, et al. Metabolic engineering of monoclonal antibody carbohydrates for antibody–drug conjugation. Bioconjugate Chem. 2013;24(10):1650–1655. doi: 10.1021/bc4002695
   PubMed Web of Science ®Google Scholar
• Jaramillo ML, Sulea T, Durocher Y, et al. A glyco-engineering approach for site-specific conjugation to fab glycans. MAbs. 2023;15(1):2149057. doi: 10.1080/19420862.2022.2149057
   PubMed Web of Science ®Google Scholar
• Jeger S, Zimmermann K, Blanc A, et al. Site‐specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angewandte Chemie. 2010;49(51):9995–9997. doi: 10.1002/anie.201004243
   Google Scholar
• Gébleux R, Briendl M, Grawunder U, et al. Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody–Drug Conjugates. In: Nuijens T, Schmidt M, editors. Enzyme-Mediated Ligation Methods. Methods in Molecular Biology. Vol. 2012. New York, NY: Humana; 2019. doi: 10.1007/978-1-4939-9546-2_1
   Google Scholar
• Wu P, Shui W, Carlson BL, et al. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc Nat Acad Sci. 2009;106(9):3000–3005. doi: 10.1073/pnas.0807820106
   PubMed Web of Science ®Google Scholar
• Kruljec N, Bratkovič T. Alternative affinity ligands for immunoglobulins. Bioconjugate Chem. 2017;28(8):2009–2030. doi: 10.1021/acs.bioconjchem.7b00335
   PubMed Web of Science ®Google Scholar
• Starovasnik MA, Braisted AC, Wells JA. Structural mimicry of a native protein by a minimized binding domain. Proc Nat Acad Sci. 1997;94(19):10080–10085. doi: 10.1073/pnas.94.19.10080
   PubMed Web of Science ®Google Scholar
• DeLano WL, Ultsch MH, de AM, et al. Convergent solutions to binding at a protein-protein interface. Science. 2000;287(5456):1279–1283. doi: 10.1126/science.287.5456.1279
   PubMed Web of Science ®Google Scholar
• Yamada K, Shikida N, Shimbo K, et al. AJICAP: affinity peptide mediated regiodivergent functionalization of native antibodies. Angew Chem. 2019;131(17):5648–5653. doi: 10.1002/ange.201814215
   Google Scholar
• Matsuda Y, Leung M, Okuzumi T, et al. A purification strategy utilizing hydrophobic interaction chromatography to obtain homogeneous species from a site-specific antibody drug conjugate produced by AJICAP™ first generation. Antibodies. 2020;9(2):16. doi: 10.3390/antib9020016
   Web of Science ®Google Scholar
• Farràs M, Miret J, Camps M, et al. Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly. MAbs. 2020;12(1):1702262. doi: 10.1080/19420862.2019.1702262
   PubMed Web of Science ®Google Scholar